Month: May 2024

VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months ended March 31, 2024 (“Q1 2024”). HighlightsThe weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 6.0% in Q1 2024, compared to 11.1% for the three months ended March 31, 2023 (“Q1 2023”). The weighted average organic royalty growth1 on a consistent currency basis was 6.0% in Q1 2024. Revenue was $15.1 million in Q1 2024, up 22.2%, compared to $12.3 million in Q1 2023. Adjusted revenue1 of $16.4 million in Q1 2024, up 20.3%, compared to $13.6 million in Q1 2023. Distributable cash1 of $9.6 million in Q1 2024, up 8.4%, compared to $8.8 million in Q1 2023. Payout ratio1 of 97.2% in Q1 2024 on...

BURR RIDGE, Ill., May 09, 2024 (GLOBE NEWSWIRE) — BankFinancial Corporation (Nasdaq – BFIN) (“BankFinancial”) filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and a Quarterly Financial and Statistical Supplement in Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) today. BankFinancial reported net income for the three months ended March 31, 2024, of $1.7 million, or $0.14 per common share. At March 31, 2024, BankFinancial had total assets of $1.480 billion, total loans of $1.008 billion, total deposits of $1.259 billion and stockholders’ equity of $156 million. In the first quarter of 2024, interest income increased by $422,000 due to our investment of scheduled loan and lease portfolio payments into short-term liquidity investments.  Interest expense increased by $327,000...

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitionsOver the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining...

Management Board of Northern Horizon Capital AS has approved the unaudited financial results of Baltic Horizon Fund (the Fund) for the three months of 2024. Our strategic ambitionsOver the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from centrally located multi-functional assets aligned with our ‘Modern City Life’ strategy. These spaces are meticulously designed to ignite, elevate and enrich the lives of modern citizens and communities. The remaining...

HIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. “The first quarter of 2024 saw us reach several important milestones, which we believe position vTv well for continued execution of our corporate and clinical development strategy,” said Paul Sekhri, Chief Executive Officer of vTv. “The proceeds of the private placement we announced at the end of February are expected to fully fund the first Phase 3 study of cadisegliatin in patients with T1D, for which we expect to report top line data in the first...